Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMP360 in Anorexia Nervosa
NCT05481736Phase 2Completed
- Sponsor
- COMPASS Pathways
- Start
- Oct 2022
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of COMP360 in anorexia nervosa (AN) (2 arms), sponsored by COMPASS Pathways. Primary endpoint: Change from baseline in the Eating Disorder Examination global score at Week 4. Started Oct 2022; status: completed.
02
Drugs
COMP360
03
Conditions
anorexia nervosa (AN)
Beyond the preview
Go deeper on NCT05481736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05481736.